Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04567927
Other study ID # 2020-01266
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 3, 2020
Est. completion date May 28, 2020

Study information

Verified date September 2020
Source Ente Ospedaliero Cantonale, Bellinzona
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of the study is to assess the frequency of the occurrence of a venous thrombosis in patients with the new Coronavirus disease, who are admitted to the Intensive Care Unit for impending respiratory failure requiring intubation and mechanical ventilation. Furthermore, the investigators aim at identifying potential risk factors for thrombosis and death.


Description:

Symptomatic infection with the severe acute respiratory syndrome coronavirus 2 ranges from mild to critical spectrum. About 80% of laboratory confirmed infections presented with mild symptoms, usually not requiring hospitalization. Critical disease requiring respiratory and/or circulatory support was reported in 5% of the subjects. Acute respiratory distress syndrome represents the most common complication in patients with severe disease. Several cases of venous thromboembolism in patients with laboratory confirmed infection have been reported, but it is unclear if this occurrence is higher in this specific patients' population. The purpose of the present study is to assess the prevalence of deep venous thrombosis in patients infected with SARS-CoV-2 admitted to the Intensive care Unit requiring invasive mechanical ventilation using vein ultrasonography.


Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Ultrasonography
Venous compression ultrasonography using real-time B-mode and colour doppler in transverse and longitudinal views

Locations

Country Name City State
Switzerland Ospedale Regionale di Bellinzona e Valli Bellinzona Ticino

Sponsors (1)

Lead Sponsor Collaborator
Chiesa Alessandro Felice

Country where clinical trial is conducted

Switzerland, 

References & Publications (6)

Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A; COVID-19 Lomb — View Citation

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 20 — View Citation

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):106 — View Citation

Wang T, Chen R, Liu C, Liang W, Guan W, Tang R, Tang C, Zhang N, Zhong N, Li S. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020 May;7(5):e362-e363. doi: 10.1016/S2352-3026(20)30109-5. Epu — View Citation

Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. — View Citation

Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observa — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Period prevalence of deep vein thrombosis (DVT) Percent (%) of patients with a DVT From date of inclusion in the study until the date of development of a DVT, date of death from any cause, or date of discharge from the ICU, whichever came first, assessed up to 3 months
See also
  Status Clinical Trial Phase
Completed NCT04527614 - Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection N/A
Not yet recruiting NCT04357613 - IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS. Phase 2
Completed NCT04453384 - Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia Phase 2
Enrolling by invitation NCT04363047 - Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19
Completed NCT04383535 - Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia N/A
Recruiting NCT04381819 - Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19
Recruiting NCT03443102 - Long-term Assessment of Organ Functions Among Survivors of Severe Acute Respiratory Syndrome N/A
Completed NCT00066209 - Investigating Severe Acute Respiratory Syndrome (SARS) N/A